Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

November 23, 2020November 23, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to ... Read more

November 5, 2020November 5, 2020

Complete Remission Reported in Patient in Ongoing Trial of APVO436

News

Aptevo Therapeutics’ investigational therapy APVO436 resulted in a patient’s complete disease remission in an ongoing trial in people with relapsed or refractory acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS), the company ... Read more

October 22, 2020October 22, 2020

FDA Approves Venclexta Combinations for Newly Diagnosed AML

News

The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta (venetoclax), in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, for treating newly diagnosed adults ... Read more

August 20, 2020August 20, 2020

Phase 1 Trial for Potential Oral Therapy CB-5339 for Myeloid Cancers Doses First Patient

News

A Phase 1 clinical trial evaluating Cleave Therapeutics’ experimental oral therapy CB-5339 as a treatment for people with relapsed or refractory acute myeloid leukemia (AML) or intermediate- to high-risk myelodysplastic syndrome (MDS) ... Read more

March 6, 2020March 23, 2020

Phase 2 Trial of Annamycin, as Less Toxic Chemo, in Advanced AML Planned

News

Moleculin has announced plans to launch a global Phase 2 clinical trial evaluating its candidate liposomal Annamycin as a less toxic and second-line therapy for relapsed or refractory acute myeloid leukemia (AML). If ... Read more